American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Feb 2023
Letter Randomized Controlled TrialA Pilot RCT of an Intervention to Improve Perception of Lung Function in Older Adults with Asthma.
-
Am. J. Respir. Crit. Care Med. · Feb 2023
Randomized Controlled TrialA Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe ARDS From COVID-19.
Rationale: There are limited therapeutic options for patients with coronavirus disease (COVID-19)-related acute respiratory distress syndrome with inflammation-mediated lung injury. Mesenchymal stromal cells offer promise as immunomodulatory agents. Objectives: Evaluation of efficacy and safety of allogeneic mesenchymal cells in mechanically-ventilated patients with moderate or severe COVID-19-induced respiratory failure. ⋯ Resolution or improvement of acute respiratory distress syndrome at 30 days was observed in 51/104 (49.0%) cell recipients and 46/106 (43.4%) control patients (odds ratio, 1.36; 95% confidence interval, 0.57-3.21). There were no infusion-related toxicities and overall serious adverse events over 30 days were similar. Conclusions: Mesenchymal cells, while safe, did not improve 30-day survival or 60-day ventilator-free days in patients with moderate and/or severe COVID-19-related acute respiratory distress syndrome.